Afatinib

Afatinib
Clinical data
Trade namesGilotrif, Giotrif, Afanix
Other namesBIBW 2992
AHFS/Drugs.comMonograph
MedlinePlusa613044
License data
Pregnancy
category
  • AU: C
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding95%
MetabolismCYP not involved
Elimination half-life37 hours
ExcretionFaeces (85%), urine (4%)
Identifiers
  • N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.239.035 Edit this at Wikidata
Chemical and physical data
FormulaC24H25ClFN5O3
Molar mass485.94 g·mol−1
3D model (JSmol)
  • CN(C)C\C=C\C(=O)Nc3cc1c(Nc(cc2Cl)ccc2F)ncnc1cc3OC4COCC4
  • InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1 checkY
  • Key:ULXXDDBFHOBEHA-CWDCEQMOSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Afatinib, sold under the brand name Gilotrif among others, is a medication which is used to treat non-small cell lung carcinoma (NSCLC).[2][3][4] It belongs to the tyrosine kinase inhibitor family of medications.[5] It is taken by mouth.[5][1]

It is mainly used to treating cases of NSCLC that harbour mutations in the epidermal growth factor receptor (EGFR) gene.[6]

It is on the World Health Organization's List of Essential Medicines.[7]

  1. ^ a b Cite error: The named reference Gilotrif FDA label was invoked but never defined (see the help page).
  2. ^ Cite error: The named reference Spreitzer was invoked but never defined (see the help page).
  3. ^ Cite error: The named reference Minkovsky was invoked but never defined (see the help page).
  4. ^ Cite error: The named reference FDA was invoked but never defined (see the help page).
  5. ^ a b Cite error: The named reference TGA was invoked but never defined (see the help page).
  6. ^ Vavalà T (2017). "Role of afatinib in the treatment of advanced lung squamous cell carcinoma". Clinical Pharmacology. 9: 147–157. doi:10.2147/CPAA.S112715. PMC 5709991. PMID 29225480.
  7. ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search